Topics About iOS App
A summary of mainstream reporting, plus the facts and perspectives it leaves out. A more honest account of each story.
Back to all stories
Left: MRI scans of a woman with breast cancer before TIL therapy show a lesion invading the chest wall (top) and metastatic lesions in the liver (bottom). Right: Scans 14 months after treatment show all lesions have disappeared. A novel approach to immunotherapy developed by researchers at the Natio
Photo: NIH Image Gallery from Bethesda, Maryland, USA | Public domain | Wikimedia Commons

Study Links GLP-1 Weight-Loss Drugs To Slower Spread Of Some Cancers

Written by TNNBot on

A retrospective study of 12,112 patients found GLP-1 weight-loss drugs were linked to slower progression to stage 4 in several obesity-related cancers, researchers said at the 2026 ASCO meeting.[1]

Patients who started GLP-1s after diagnosis had about 50% lower progression to stage 4 non-small cell lung cancer and 43% lower progression in breast cancer compared with DPP-4 inhibitor users.[1] Colorectal and liver cancer patients on GLP-1s showed 31% and 38% lower progression to stage 4 disease respectively, while differences in prostate, pancreatic and kidney cancers were not statistically significant.[1] Tumors with higher GLP-1 receptor expression were tied to roughly a one-third reduction in death risk during follow-up.[1]

The retrospective analysis drew on 12,112 patients with stage 1-3 obesity-related cancers treated in real-world settings.[1] Researchers compared patients who began GLP-1 drugs after diagnosis to those taking DPP-4 inhibitors, a different class of diabetes drugs used as a comparator.[1] Because the study is retrospective and has not been peer reviewed, investigators cautioned the results do not prove that GLP-1 drugs caused the slower spread and urged randomized trials.[1]

The study will be formally presented at the 2026 ASCO Annual Meeting and has not yet undergone peer review, limiting causal conclusions.[1]

  1. Fox News
Public Health & Medicine Cancer Research
Show source details & analysis (1 source)

📌 Key Facts

  • The retrospective study included 12,112 patients with stage 1–3 obesity-related cancers treated in real-world settings.
  • Patients who began GLP-1 drugs after diagnosis had 50% lower progression to stage 4 non-small cell lung cancer and 43% lower progression in breast cancer compared with DPP-4 inhibitor users.
  • Colorectal and liver cancer patients on GLP-1s showed 31% and 38% lower progression to stage 4 disease, respectively, while differences in prostate, pancreatic and kidney cancers were not statistically significant.
  • Tumors with higher GLP-1 receptor expression were associated with roughly a one‑third reduction in death risk during follow-up.
  • The study will be formally presented at the 2026 ASCO Annual Meeting and has not yet undergone peer review, limiting causal conclusions.

📰 Source Timeline (1)

Follow how coverage of this story developed over time

May 26, 2026
11:00 AM
Ozempic-style drugs linked to major slowdown in cancer spread, new study finds
Fox News